LARTRUVO
PeakmAbBLAInjectionInjectablePriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARTRUVO is a monoclonal antibody (mAb) therapeutic approved by the FDA in October 2016 as an injectable biologic. The specific indication, mechanism of action, and patient population cannot be determined from available data.
Peak
Product is at peak commercial stage; team size and hiring are likely stable with focus on market maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARTRUVO currently shows zero linked job openings, indicating stable team structures with limited active hiring. Roles on this product typically involve brand management, field engagement, and medical support for a mature biologic therapeutic.
Brand ManagerMedical Science Liaison
Worked on LARTRUVO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.